Sanofi Consumer Healthcare IndiaNSE:SANOFICONR +0.18%21 ROA % is 49.58% as of Mar. 2026, which is 4% above its 10-year median of 47.74. GuruFocus rates NSE:SANOFICONR with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Sanofi Consumer Healthcare India ranks better than 99.2% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Sanofi Consumer Healthcare India's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹2,712 Mil.
Sanofi Consumer Healthcare India's average Total Assets over the quarter that ended in Mar. 2026 was ₹5,470 Mil. Therefore, Sanofi Consumer Healthcare India's annualized ROA % for the quarter that ended in Mar. 2026 was 49.58%.
NSE:SANOFICONR'
s ROA % Range Over the Past 10 Years
Min: 46.61 Med: 47.74 Max: 55.25
Current: 55.25
During the past 3 years, Sanofi Consumer Healthcare India's highest ROA % was 55.25%. The lowest was 46.61%. And the median was 47.74%.
NSE:SANOFICONR's ROA % is ranked better than 99.2% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 2.72
vs NSE:SANOFICONR: 55.25
Sanofi Consumer Healthcare India (NSE:SANOFICONR) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Sanofi Consumer Healthcare India ROA % Related Terms
Sanofi Consumer Healthcare India ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SANOFICONR vs LLY, JNJ, ABBV: ROA % Comparison
For the Drug Manufacturers - General subindustry, Sanofi Consumer Healthcare India's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi Consumer Healthcare India ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi Consumer Healthcare India's ROA % distribution charts can be found below:
* The bar in red indicates where Sanofi Consumer Healthcare India's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a ROA % of 49.58% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sanofi Consumer Healthcare India and its competitors. This is near median its historical median of 47.74. Over the past decade, Sanofi Consumer Healthcare India's ROA % has ranged from 46.61 to 55.25. According to the industry distribution chart, Sanofi Consumer Healthcare India ranks #8 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 0.8%.
Is Sanofi Consumer Healthcare India's ROA % too high?
Sanofi Consumer Healthcare India's current ROA % of 49.58% is near median its 10-year median of 47.74. Over the past 10 years, this metric has ranged from a low of 46.61 to a high of 55.25. The Drug Manufacturers industry median ROA % is 2.72. Sanofi Consumer Healthcare India's value of 49.58% is 1722.8% above this industry median. Based on the distribution chart, Sanofi Consumer Healthcare India ranks #8 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanofi Consumer Healthcare India has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi Consumer Healthcare India's ROA % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi Consumer Healthcare India ranks #8 out of 1005 companies for ROA %. This places Sanofi Consumer Healthcare India in the top 1% of its industry — outperforming the majority of peers. The industry median ROA % is 2.72. Sanofi Consumer Healthcare India's value of 49.58% is 1722.8% above this benchmark. Historically, Sanofi Consumer Healthcare India's own ROA % has ranged from 46.61 to 55.25 over the past decade. While the company's 10-year median is 47.74 vs. the industry median of 2.72, Sanofi Consumer Healthcare India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.72, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi Consumer Healthcare India's current ROA % of 49.58% is 1722.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sanofi Consumer Healthcare India and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi Consumer Healthcare India's current ROA % is 49.58%, which is near median its own 10-year median of 47.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi Consumer Healthcare India stock overvalued right now?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a current ROA % of 49.58%. The current ROA % is 49.58%, which is near median its 10-year median of 47.74 and 1722.8% above the Drug Manufacturers industry median of 2.72. Sanofi Consumer Healthcare India's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Sanofi Consumer Healthcare India (NSE:SANOFICONR), the current ROA % is 49.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sanofi Consumer Healthcare India Business Description
Sanofi Consumer Healthcare India Ltd is mainly engaged in the business of manufacturing and trading of drugs and pharmaceutical products. The Company also has various independent contract/third-party manufacturers based across the country and provides business support services to its group entity in India. Its products include Allergy Relief (Allegra), Pain Care (Combiflam), and Physical Wellness (DePURA). The Company sells its products in India through independent distributors and outside India. Its operations are limited to one segment, namely Pharmaceutical Business. The Company operates in India, which generates the maximum revenue, and Outside India.
21GF Score
Get the complete analysis for NSE:SANOFICONR
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SANOFICONR has been successfully added to your 
